Stevanato Group S.p.A.
NYQ: STVNLive Quote
📈 ZcoreAI Score
Our AI model analyzes Stevanato Group S.p.A.'s price action across multiple timeframes using regression channels and statistical scoring.
Get STVN Z-Score →About Stevanato Group S.p.A.
Healthcare
Medical Instruments & Supplies
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. The company offers drug containment solutions comprising pre-fillable syringes, cartridges, vials, and ampoules; in-vitro diagnostic solutions; drug delivery systems, including pen injectors, auto-injectors, and wearable injectors; diagnostic laboratory consumables; analytical and regulatory support services; medical devices; pharmaceutical visual inspection machines; assembling and packaging machines; glass converting machines; and after-sales services, such as line optimization and line conversions, training, logistics, spare parts and maintenance services. It also provides contract development and manufacturing services for customer-owned drug delivery devices. The company serves pharmaceutical, biotechnology, diagnostics, and life sciences companies; and drug products, glass packaging, and fill and finish contract manufacturers. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.
📊 Fundamental Analysis
Stevanato Group S.p.A. demonstrates a profit margin of 11.8%, which is below the sector average, suggesting competitive pressure.
The company recently reported 4.8% revenue growth, which is modest compared to its industry peers.
Return on Equity (ROE) is 9.7%, which suggests room for improvement in capital utilization.
At a current price of $13.52, STVN currently trades near the bottom of its 52-week range (4%), indicating potential value or weakness (Range: $12.89 - $28.00).
💰 Valuation Insight
STVN is valued broadly in line with the sector at a PE of 22.92. Analysts expect earnings growth, as indicated by a lower forward PE.
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
🔴
Revenue Growth
Weak
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$3.69B
Trailing P/E
22.92
Forward P/E
15.85
Beta (5Y)
0.62
52W High
$28.00
52W Low
$12.89
Avg Volume
722K
Day High
Day Low